By: Andrew Neiman

A new House bill (H.R. 5587), introduced on January 13, 2020 calls for amending the Federal Food, Drug, and Cosmetic Act to change the way the Food and Drug Administration regulates hemp derived CBD products. Specifically, the bill would order the FDA to allow the marketing of cannabidiol (“CBD”) as a dietary supplement and food additive.

Fortis attorney Andrew Neiman provides insight into the changing CBD marketplace for Benzinga. To read more from this article, please follow the link located here.